Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MediWound Ltd.
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
August 15, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
August 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
August 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Second Quarter 2024 Financial Results
August 02, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
July 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
July 16, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces $25 Million Strategic Private Placement Financing
July 15, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
May 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report First Quarter 2024 Financial Results
May 22, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
February 12, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in Two Upcoming Investor Conferences
February 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
January 09, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
December 28, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
December 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
ENLV
MDWD
MediWound to Report Third Quarter 2023 Financial Results
November 14, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
November 13, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
November 08, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
October 11, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MMM
MediWound Deploys NexoBrid® for Emergency Supply
October 09, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
September 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
September 11, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MDXG
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.